Chromo Immunohistochemistry at Lahore PCR Lab

Chromo Immunohistochemistry at Lahore PCR Lab

Chromo Immunohistochemistry (IHC) represents a cornerstone of modern diagnostic pathology, bridging the gap between microscopic cellular morphology and molecular profiling. At Lahore PCR Lab in Lahore, Pakistan, this advanced diagnostic modality is utilized to identify specific cellular proteins (antigens) within tissue sections. By exploiting the principle of highly specific antigen-antibody binding, our pathologists can visualize the precise localization of target proteins under a standard light microscope. The “chromo” prefix refers to the chromogenic detection system, where an enzyme-catalyzed reaction produces a colored precipitate (typically brown or red) at the site of the antigen. This technique is indispensable for cancer diagnosis, tumor subtyping, prognostic evaluation, and the selection of targeted therapeutic regimens.

The diagnostic value of Chromo Immunohistochemistry lies in its ability to provide objective, molecular-level data from a standard tissue biopsy. While routine Hematoxylin and Eosin (H&E) staining reveals the architectural and cytological features of a tissue, it often cannot differentiate between morphologically identical tumors. Chromo IHC solves this diagnostic challenge by highlighting specific lineage markers, oncogenes, tumor suppressors, and proliferation indices. This level of precision is critical in oncology, where treatment protocols are increasingly tailored to the molecular profile of the individual tumor, ensuring patients receive the most effective targeted therapies.

Clinical Procedure: What to Expect

Patient Preparation

Because Chromo Immunohistochemistry is a specialized laboratory test performed on tissue specimens that have already been collected, there is no direct physical preparation required for the patient on the day of the IHC analysis itself. However, the following guidelines are crucial for ensuring a seamless diagnostic process:

• Submission of Tissue Blocks: Patients must submit their Formalin-Fixed Paraffin-Embedded (FFPE) tissue blocks (commonly referred to as “paraffin blocks”) along with the corresponding Hematoxylin and Eosin (H&E) stained slides from the primary biopsy.
• Clinical Documentation: It is highly recommended to provide the original histopathology report, relevant radiological findings, and a brief clinical history to assist the pathologist in selecting the appropriate antibody panel.
• Biopsy Preparation: If the primary biopsy has not yet been performed, patients must follow the specific pre-operative instructions provided by their surgeon or interventional radiologist, which may include fasting or temporarily discontinuing blood-thinning medications.
• Sample Integrity: Ensure that the tissue specimen was fixed in 10% neutral buffered formalin within the recommended cold ischemia time to preserve protein antigenicity.

During the Procedure

The laboratory workflow of Chromo Immunohistochemistry at Lahore PCR Lab is a highly standardized, multi-step process executed by skilled histotechnologists and evaluated by consultant pathologists:

• Sectioning: Ultra-thin sections (typically 3 to 5 micrometers thick) are cut from the paraffin block using a high-precision microtome and mounted onto positively charged glass slides to prevent tissue detachment.
• Deparaffinization and Rehydration: The slides are heated and treated with clearing agents (such as xylene) and graded alcohols to remove the paraffin wax and rehydrate the tissue.
• Antigen Retrieval: Formalin fixation cross-links proteins, which can mask target epitopes. Slides undergo Heat-Induced Epitope Retrieval (HIER) using specialized buffer solutions in a controlled temperature environment to unmask these target sites.
• Primary Antibody Incubation: The tissue is incubated with highly specific, clinically validated primary antibodies designed to bind exclusively to the target antigen of interest.
• Secondary Antibody and Enzyme Conjugation: A secondary antibody, conjugated with an enzyme such as Horseradish Peroxidase (HRP) or Alkaline Phosphatase (AP), is applied to bind to the primary antibody, amplifying the signal.
• Chromogen Visualization: A chromogenic substrate, such as 3,3’-Diaminobenzidine (DAB) or Aminoethyl Carbazole (AEC), is introduced. The enzyme catalyzes a reaction that deposits an insoluble, highly visible colored precipitate (brown for DAB, red for AEC) at the precise site of the antigen.
• Counterstaining and Mounting: The slides are counterstained with hematoxylin to provide contrast by coloring cell nuclei blue, then dehydrated, cleared, and sealed with a coverslip for microscopic analysis.

When is a Chromo Immunohistochemistry Performed?

Breast Cancer Subtyping and Receptor Status

Chromo Immunohistochemistry is routinely performed on all newly diagnosed breast cancers to determine the expression of Estrogen Receptors (ER), Progesterone Receptors (PR), and Human Epidermal Growth Factor Receptor 2 (HER2). Patients presenting with breast lumps, abnormal mammograms, or nipple discharge undergo a biopsy, and the resulting tissue is analyzed via IHC. This testing is crucial because it directly dictates systemic therapy: hormone receptor-positive cancers are treated with endocrine therapies (like tamoxifen or aromatase inhibitors), while HER2-positive cancers are candidates for targeted anti-HER2 monoclonal antibodies (such as trastuzumab).

Classification and Lineage Determination of Lymphomas

When a patient presents with persistent lymphadenopathy, unexplained fevers, night sweats, and weight loss, a lymph node biopsy is performed. Because lymphoid neoplasms can look highly similar under routine microscopy, pathologists utilize Chromo IHC to differentiate between Hodgkin Lymphoma and Non-Hodgkin Lymphoma, and to further classify them into B-cell or T-cell lineages. By applying a panel of cluster of differentiation (CD) markers (such as CD20, CD3, CD30, and CD15), the pathologist can precisely identify the specific subtype of lymphoma, which is essential for selecting the correct chemotherapy protocol.

Identifying the Primary Site of Metastatic Tumors

In cases where a patient presents with metastatic disease—such as lesions in the liver, lungs, or bones—without an obvious primary tumor, Chromo IHC is employed to determine the tissue of origin. Patients may experience generalized symptoms like bone pain, abdominal distension, or shortness of breath. By analyzing a biopsy of the metastatic site with lineage-specific markers like Cytokeratin 7 (CK7), Cytokeratin 20 (CK20), Thyroid Transcription Factor-1 (TTF-1), and GATA3, pathologists can trace the lineage of the tumor cells back to their primary organ (e.g., lung, colon, breast, or thyroid), allowing for targeted systemic treatment.

Assessment of Tumor Proliferation Index

Physicians frequently request Chromo IHC for the Ki-67 protein to evaluate the growth fraction of a tumor. This is particularly important in neuroendocrine tumors, breast cancers, and lymphomas. A high Ki-67 proliferation index indicates a rapidly dividing, aggressive tumor, which often correlates with a higher histological grade and a more urgent need for systemic chemotherapy. Conversely, a low Ki-67 index suggests a more indolent disease course, which may allow for conservative management or localized therapies.

Differentiating Benign from Malignant Lesions

In challenging diagnostic cases, such as atypical intraductal proliferations in the breast or atypical small acinar proliferations in the prostate, routine H&E staining may be inconclusive. Patients undergoing biopsies for elevated PSA levels or suspicious breast calcifications benefit from IHC panels designed to highlight the presence or absence of a basal cell layer. For example, the loss of basal markers (like p63 or High Molecular Weight Cytokeratin) combined with the overexpression of tumor markers (like AMACR in prostate cancer) confirms a malignant diagnosis, preventing both under-treatment and unnecessary radical surgery.

What Does a Chromo Immunohistochemistry Detect?

Chromo Immunohistochemistry is capable of detecting a vast array of diagnostic, prognostic, and predictive biomarkers within tissue specimens. The specific markers evaluated depend on the clinical scenario and the organ system involved:

• Estrogen Receptor (ER): Detects nuclear hormone receptors in breast carcinomas; guides endocrine therapy.
• Progesterone Receptor (PR): Evaluates functional hormone receptor pathways in breast and endometrial tissues.
• HER2/neu: Identifies transmembrane glycoprotein overexpression in breast and gastric cancers to determine eligibility for trastuzumab.
• Ki-67: Measures the percentage of actively dividing cells, serving as a key marker of cellular proliferation.
• CD20: A pan-B-cell marker used to identify B-cell lymphomas, such as Diffuse Large B-Cell Lymphoma (DLBCL).
• CD3: A pan-T-cell marker utilized to identify T-cell lineages in reactive and neoplastic lymphoid infiltrates.
• Cytokeratin 7 (CK7): Expressed in glandular epithelia of the lung, breast, and upper gastrointestinal tract; helps narrow down tumor origin.
• Cytokeratin 20 (CK20): Primarily expressed in colonic and urothelial epithelia; useful in identifying colorectal metastases.
• TTF-1 (Thyroid Transcription Factor-1): Confirms primary lung adenocarcinomas and thyroid neoplasms.
• PSA (Prostate-Specific Antigen): Confirms the prostatic origin of metastatic adenocarcinomas in male patients.
• Synaptophysin: A membrane glycoprotein of synaptic vesicles, indicating neuroendocrine differentiation.
• Chromogranin A: An acidic glycoprotein found in secretory granules of neuroendocrine cells; confirms neuroendocrine tumors.
• S100 Protein: Detects neural crest-derived tissues, highly sensitive for malignant melanoma and schwannomas.
• Melan-A / MART-1: A lineage-specific marker for melanocytic differentiation, crucial in diagnosing amelanotic melanomas.
• CD30: Expressed on Reed-Sternberg cells in Hodgkin Lymphoma and in Anaplastic Large Cell Lymphoma (ALCL).
• CD15: Used in conjunction with CD30 to confirm the diagnosis of Classical Hodgkin Lymphoma.
• p53: Detects abnormal accumulation of the mutated p53 tumor suppressor protein, common in high-grade carcinomas.
• p63: Highlights myoepithelial cells in breast tissue and basal cells in prostate tissue; helps rule out invasive carcinoma.
• AMACR (Alpha-Methylacyl-CoA Racemase): Overexpressed in prostatic adenocarcinoma; used to confirm malignancy in needle biopsies.
• GATA3: A highly sensitive marker for breast and urothelial carcinomas.
• PAX8: Expressed in renal, thyroid, and Mullerian (ovarian/endometrial) tumors; aids in subtyping metastatic carcinomas.
• Vimentin: A mesenchymal marker used to classify sarcomas and evaluate epithelial-mesenchymal transition.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we understand that waiting for pathology results can be an anxious time for patients and their families. Because Chromo Immunohistochemistry requires meticulous tissue processing, antigen retrieval, multi-step antibody staining, and detailed microscopic evaluation by our consultant pathologists, the turnaround time typically ranges from 3 to 5 working days from the receipt of the tissue block. This timeline ensures that all quality control checks, including positive and negative tissue controls, are fully verified before a final diagnosis is rendered.

Patients and referring physicians can easily access reports through our secure online portal. Once the report is finalized and signed off by our specialist pathologist, an automated SMS notification is sent to the patient with a direct link to download the PDF report. Physical copies of the reports can also be collected from our main facility in Lahore or any of our designated collection centers.

Chromo Immunohistochemistry Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Hormone Receptors (ER/PR)	Negative in non-target tissues; normal physiological expression in benign breast lobules.	Strong nuclear positivity in hormone-sensitive breast and endometrial adenocarcinomas.
HER2 Oncoprotein	Membrane staining absent or faint/incomplete in normal epithelial cells (Score 0 or 1+).	Strong, complete circumferential membrane staining in >10% of tumor cells (Score 3+, positive).
Ki-67 Proliferation Index	Low expression (typically <5%) in quiescent, normal resting tissues.	Elevated expression (e.g., >30% to 90%) in high-grade, rapidly growing malignancies.
Lymphoid Lineage (CD20/CD3)	Balanced, organized distribution of B and T cells within normal lymph node compartments.	Monoclonal expansion of CD20+ B-cells or CD3+ T-cells, disrupting normal nodal architecture.
Epithelial Cytokeratins (CK7/CK20)	Organ-specific expression matching the tissue of origin (e.g., CK7+/CK20- in normal lung).	Abnormal expression profile indicating metastatic disease (e.g., CK7-/CK20+ in liver biopsy).
Neuroendocrine Markers	Absent or restricted to specialized neuroendocrine cells in normal mucosa.	Diffuse cytoplasmic positivity for Synaptophysin and Chromogranin in neuroendocrine tumors.
Basal/Myoepithelial Layer (p63)	Continuous, intact basal layer surrounding normal glands and ducts.	Complete loss of the p63-positive basal layer, indicating invasive carcinoma.
Melanocytic Markers (S100/Melan-A)	Restricted to normal melanocytes in the basal layer of the epidermis.	Diffuse, strong positivity in dermal nests, confirming malignant melanoma.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for Chromo Immunohistochemistry?

• Expert Pathologists: Our laboratory features a team of highly qualified consultant pathologists with specialized training in surgical pathology and immunohistochemistry.
• Advanced Automated Platforms: We utilize state-of-the-art automated IHC staining systems to ensure consistent, reproducible, and highly precise staining quality.
• Comprehensive Antibody Library: Lahore PCR Lab maintains an extensive panel of clinically validated primary antibodies for diverse diagnostic needs.
• Rigorous Quality Control: We run verified positive and negative tissue controls with every batch to guarantee diagnostic accuracy and eliminate false results.
• Integrated Diagnostics: We seamlessly correlate IHC findings with routine histopathology and molecular PCR testing for a comprehensive diagnostic picture.
• Patient-Focused Care: We prioritize patient comfort, offering clear guidance on sample submission and transparent communication throughout the process.
• Convenient Digital Access: Patients can easily download their reports online via our secure portal, reducing the need for unnecessary travel.
• Trusted by Clinicians: Lahore PCR Lab is a preferred diagnostic partner for oncologists and surgeons across Lahore and Punjab due to our commitment to accuracy.